Makhija said the Phase II study is now closed, and researchers are in the planning stages for a larger Phase 3 study of pertuzumab set to include hundreds of U.S. women.
Pertuzumab is approved only for experimental uses. It falls within a class of anticancer agents called monoclonal antibodies. Such drugs target key signaling pathways within cells that can stop or slow tumor growth.
'/>"/>
| Contact: Troy Goodman tdgoodman@uab.edu 205-934-8938 University of Alabama at Birmingham Source:Eurekalert |